JointHealth™ express November 20, 2015
CADTH's Request for Advice on the Canadian Drug Expert Committee's recommendations for denosumab for osteoporosis
Would you like to provide input to inform CADTH's report and CDEC's advice?
The Canadian Agency for Drugs and Technologies in Health (CADTH) has received a request for advice for denosumab (Prolia®). The request for advice comes from their participating drug plans, and can result in a revised Canadian Drug Expert Committee (CDEC) recommendation or a CDEC Record of Advice.
CADTH is interested in learning:
In 2011, CDEC recommended that: denosumab be listed for women with postmenopausal osteoporosis who would otherwise be eligible for jurisdictional funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to hypersensitivity or abnormalities of the esophagus (e.g., esophageal stricture or achalasia), and have at least two of the following:
CADTH's Request for Advice on the Canadian Drug Expert Committee's recommendations for denosumab for osteoporosis
Would you like to provide input to inform CADTH's report and CDEC's advice?
The Canadian Agency for Drugs and Technologies in Health (CADTH) has received a request for advice for denosumab (Prolia®). The request for advice comes from their participating drug plans, and can result in a revised Canadian Drug Expert Committee (CDEC) recommendation or a CDEC Record of Advice.
CADTH is interested in learning:
- How should fracture risk be best described?
- Is there a place for age (>75 years) or bone density scores, or are these adequately captured within fracture risk?
- How should bisphosphonate failure be best described?
- How should bisphosphonate intolerance be best described?
In 2011, CDEC recommended that: denosumab be listed for women with postmenopausal osteoporosis who would otherwise be eligible for jurisdictional funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to hypersensitivity or abnormalities of the esophagus (e.g., esophageal stricture or achalasia), and have at least two of the following:
- Age >75 years
- A prior fragility fracture
- A bone mineral density (BMD) T-score ? ?2.5.
- High fracture risk defined as either: a moderate 10 year fracture risk (10% to 20%) with a prior fragility fracture; or a high 10 year fracture risk (?20%) as defined by either the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the World Health Organization's Fracture Risk Assessment (FRAX) tool.
- Contraindication to oral bisphosphonates